Drugs / Tianshu capsule
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02035111 | Mar 2014 → Apr 2015 | migraine disorder | Jiangsu Kanion Pharmaceutical Co., Ltd | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tianshu capsule | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02035111 ↗ |
| Known as | TSC | “Tianshu capsule (TSC), a formula of traditional Chinese medicine, has been widely used in clinical practice for prophylactic treatment of headaches in China.” PMID 31842860 ↗ Dec 2019 |
| Modality | Traditional medicine (herbal / TCM) | “Tianshu capsule (TSC), a formula of traditional Chinese medicine” PMID 31842860 ↗ Dec 2019 |
| Route | Oral | “Four Tianshu capsules (0.34 g per capsule) by oral three times a day for 12 weeks.” NCT02035111 ↗ |